AAPL327.46+2.50 (+0.77%) ▲|ABBV260.94-0.78 (-0.30%) ▼|ABT108.42-2.05 (-1.86%) ▼|ACN193.77+6.09 (+3.24%) ▲|ADBE285.34+5.55 (+1.98%) ▲|AMAT435.64-2.82 (-0.64%) ▼|AMD456.72-0.34 (-0.07%) ▼|AMGN442.96+0.12 (+0.03%) ▲|AMT178.11+5.19 (+3.00%) ▲|AMZN258.46+3.48 (+1.36%) ▲|AVGO358.20-9.04 (-2.46%) ▼|AXP330.43+0.45 (+0.14%) ▲|BA210.45+1.58 (+0.76%) ▲|BAC63.15+0.55 (+0.88%) ▲|BKNG195.95-3.65 (-1.83%) ▼|BLK1,121.69+14.61 (+1.32%) ▲|BMY67.68+0.02 (+0.02%) ▲|BNY164.06+2.02 (+1.25%) ▲|BRK-B507.69+2.45 (+0.48%) ▲|C138.22+3.88 (+2.88%) ▲|CAT794.72+2.44 (+0.31%) ▲|CL89.94-0.16 (-0.18%) ▼|CMCSA26.65-0.17 (-0.62%) ▼|COF220.72+4.12 (+1.90%) ▲|COP135.89-1.31 (-0.95%) ▼|COST928.12-0.36 (-0.04%) ▼|CRM265.47+8.54 (+3.32%) ▲|CSCO108.83-0.63 (-0.57%) ▼|CVS96.89-0.34 (-0.35%) ▼|CVX211.82+0.04 (+0.02%) ▲|DE686.59-11.78 (-1.69%) ▼|DHR210.43+0.52 (+0.25%) ▲|DIS107.35-0.63 (-0.58%) ▼|DUK121.50+0.94 (+0.78%) ▲|EMR150.08+1.10 (+0.74%) ▲|FDX322.88+6.34 (+2.00%) ▲|GD364.10+0.03 (+0.01%) ▲|GE332.68+3.18 (+0.96%) ▲|GEV940.50+18.56 (+2.01%) ▲|GILD150.83+1.22 (+0.82%) ▲|GM87.02+2.15 (+2.53%) ▲|GOOG339.67+5.89 (+1.76%) ▲|GOOGL343.02+5.90 (+1.75%) ▲|GS1,035.87+31.45 (+3.13%) ▲|HD318.02+1.84 (+0.58%) ▲|HON207.47+1.40 (+0.68%) ▲|IBM233.06+1.36 (+0.59%) ▲|INTC91.07+1.02 (+1.13%) ▲|INTU346.71+3.77 (+1.10%) ▲|ISRG370.58-1.31 (-0.35%) ▼|JNJ278.18+2.97 (+1.08%) ▲|JPM362.35+6.13 (+1.72%) ▲|KO89.11+0.87 (+0.98%) ▲|LIN482.68-3.18 (-0.65%) ▼|LLY1,155.47-4.61 (-0.40%) ▼|LMT531.36-0.19 (-0.04%) ▼|LOW202.71+2.87 (+1.44%) ▲|LRCX290.89+2.57 (+0.89%) ▲|MA584.95-3.19 (-0.54%) ▼|MCD259.62-1.33 (-0.51%) ▼|MDLZ61.39-1.07 (-1.71%) ▼|MDT92.46+0.28 (+0.30%) ▲|META613.49+20.64 (+3.48%) ▲|MMM168.13-0.63 (-0.37%) ▼|MO69.78+0.22 (+0.31%) ▲|MRK151.65+0.01 (+0.01%) ▲|MS217.00+5.18 (+2.44%) ▲|MSFT511.22+14.40 (+2.90%) ▲|MU947.50-8.58 (-0.90%) ▼|NEE84.09+0.99 (+1.19%) ▲|NFLX82.69-0.05 (-0.05%) ▼|NKE38.76+0.52 (+1.36%) ▲|NOW145.75+9.03 (+6.60%) ▲|NVDA229.46+5.05 (+2.25%) ▲|ORCL155.64+9.89 (+6.78%) ▲|PEP140.32-0.20 (-0.14%) ▼|PFE28.72-0.30 (-1.03%) ▼|PG147.30-0.34 (-0.23%) ▼|PLTR183.78+14.32 (+8.45%) ▲|PM187.37-0.57 (-0.30%) ▼|QCOM169.38+0.34 (+0.20%) ▲|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO616.47+7.93 (+1.30%) ▲|TMUS188.54+1.24 (+0.66%) ▲|TSLA380.80+23.79 (+6.66%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|AAPL327.46+2.50 (+0.77%) ▲|ABBV260.94-0.78 (-0.30%) ▼|ABT108.42-2.05 (-1.86%) ▼|ACN193.77+6.09 (+3.24%) ▲|ADBE285.34+5.55 (+1.98%) ▲|AMAT435.64-2.82 (-0.64%) ▼|AMD456.72-0.34 (-0.07%) ▼|AMGN442.96+0.12 (+0.03%) ▲|AMT178.11+5.19 (+3.00%) ▲|AMZN258.46+3.48 (+1.36%) ▲|AVGO358.20-9.04 (-2.46%) ▼|AXP330.43+0.45 (+0.14%) ▲|BA210.45+1.58 (+0.76%) ▲|BAC63.15+0.55 (+0.88%) ▲|BKNG195.95-3.65 (-1.83%) ▼|BLK1,121.69+14.61 (+1.32%) ▲|BMY67.68+0.02 (+0.02%) ▲|BNY164.06+2.02 (+1.25%) ▲|BRK-B507.69+2.45 (+0.48%) ▲|C138.22+3.88 (+2.88%) ▲|CAT794.72+2.44 (+0.31%) ▲|CL89.94-0.16 (-0.18%) ▼|CMCSA26.65-0.17 (-0.62%) ▼|COF220.72+4.12 (+1.90%) ▲|COP135.89-1.31 (-0.95%) ▼|COST928.12-0.36 (-0.04%) ▼|CRM265.47+8.54 (+3.32%) ▲|CSCO108.83-0.63 (-0.57%) ▼|CVS96.89-0.34 (-0.35%) ▼|CVX211.82+0.04 (+0.02%) ▲|DE686.59-11.78 (-1.69%) ▼|DHR210.43+0.52 (+0.25%) ▲|DIS107.35-0.63 (-0.58%) ▼|DUK121.50+0.94 (+0.78%) ▲|EMR150.08+1.10 (+0.74%) ▲|FDX322.88+6.34 (+2.00%) ▲|GD364.10+0.03 (+0.01%) ▲|GE332.68+3.18 (+0.96%) ▲|GEV940.50+18.56 (+2.01%) ▲|GILD150.83+1.22 (+0.82%) ▲|GM87.02+2.15 (+2.53%) ▲|GOOG339.67+5.89 (+1.76%) ▲|GOOGL343.02+5.90 (+1.75%) ▲|GS1,035.87+31.45 (+3.13%) ▲|HD318.02+1.84 (+0.58%) ▲|HON207.47+1.40 (+0.68%) ▲|IBM233.06+1.36 (+0.59%) ▲|INTC91.07+1.02 (+1.13%) ▲|INTU346.71+3.77 (+1.10%) ▲|ISRG370.58-1.31 (-0.35%) ▼|JNJ278.18+2.97 (+1.08%) ▲|JPM362.35+6.13 (+1.72%) ▲|KO89.11+0.87 (+0.98%) ▲|LIN482.68-3.18 (-0.65%) ▼|LLY1,155.47-4.61 (-0.40%) ▼|LMT531.36-0.19 (-0.04%) ▼|LOW202.71+2.87 (+1.44%) ▲|LRCX290.89+2.57 (+0.89%) ▲|MA584.95-3.19 (-0.54%) ▼|MCD259.62-1.33 (-0.51%) ▼|MDLZ61.39-1.07 (-1.71%) ▼|MDT92.46+0.28 (+0.30%) ▲|META613.49+20.64 (+3.48%) ▲|MMM168.13-0.63 (-0.37%) ▼|MO69.78+0.22 (+0.31%) ▲|MRK151.65+0.01 (+0.01%) ▲|MS217.00+5.18 (+2.44%) ▲|MSFT511.22+14.40 (+2.90%) ▲|MU947.50-8.58 (-0.90%) ▼|NEE84.09+0.99 (+1.19%) ▲|NFLX82.69-0.05 (-0.05%) ▼|NKE38.76+0.52 (+1.36%) ▲|NOW145.75+9.03 (+6.60%) ▲|NVDA229.46+5.05 (+2.25%) ▲|ORCL155.64+9.89 (+6.78%) ▲|PEP140.32-0.20 (-0.14%) ▼|PFE28.72-0.30 (-1.03%) ▼|PG147.30-0.34 (-0.23%) ▼|PLTR183.78+14.32 (+8.45%) ▲|PM187.37-0.57 (-0.30%) ▼|QCOM169.38+0.34 (+0.20%) ▲|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO616.47+7.93 (+1.30%) ▲|TMUS188.54+1.24 (+0.66%) ▲|TSLA380.80+23.79 (+6.66%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|
29.8 C
New York
Thursday, September 3, 2026

Tag: biopharmaceutical company

newssourceFORcompanyinformationcontent1releasesmarket

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

Avicanna Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrantsSEATTLE, June 12, 2026...

Traws Pharma Provides Regulatory Update on Influenza Program

NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...

Akeso’s Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio

HONG KONG, June 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab...

Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and...

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile —

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiopharmaceutical company

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers